About Kodiak Sciences Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://kodiak.com/
Frequently Asked Questions
What is the 52-week range for KOD?
The 52-week high is $104 and the 52-week low is $10.94.
What is the P/E ratio for KOD?
The P/E ratio data is currently unavailable.
What is the dividend yield for KOD?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -273.23%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 10.85.
Analyst Recommendation Trends
Wall Street analyst consensus for KOD over the last few months:
Latest KOD News
PepsiCo, Delta Lead Upcoming Earnings Slate; Fed Minutes In Focus
Preview next weekâs key market eventsâPMI, Fed minutes, jobless claimsâand top earnings (PepsiCo, Delta). Read here for more details.
Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuit
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
The latest installment in BioPharma Dive’s data visualization series features a closer look at Kodiak’s stock performance and Hengrui's ties with U.S. and European drugmakers.
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
Kodiak Sciences reported strong endpoint results for its late-stage eye injection candidate, sending its stock soaring.
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
Kodiak Sciences tripled in a single session after its eye drug cleared a pivotal trial, but a cash-burning biotech with no revenue and a likely share offering complicates any case for chasing the move.
This is the top biotech stock pick from B Riley Securities
Investing.com -- B. Riley Securities reiterated its Buy rating and $37 price target on 4D Molecular Therapeutics, citing the launch of a Phase 3 trial in diabetic macular edema and encouraging two-year data for its lead gene therapy candidate.
KOD Stock Soars 178% on Positive Wet AMD Data as BLA Filing Nears
Kodiak surges 178% as positive phase III DAYBREAK data show Zenkuda and tabirafusp-ted met key endpoints against Eylea.
What Does Regeneron Pharmaceuticals (REGN) Need To Prove In Eye Disease Now?
Regeneron Pharmaceuticals (NasdaqGS: REGN) faces fresh pressure after Kodiak Sciences reported new Phase 3 data on its eye drugs. Kodiak said Zenkuda and tabirafusp alfa tedromer matched Eylea on primary Phase 3 endpoints for macular degeneration treatment. The trial reported similar vision outcomes with Kodiak's candidates given roughly every six months versus Eylea's current eight week dosing interval. This comparison between Eylea and Kodiak's longer interval injections is only one piece...
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.
New Eye Treatment Boosts Kodiak Into Ranks of Resurgent Biotechs
Its latest study suggested its drug candidates improved eyesight for patients with wet macular degeneration as much as the leading treatment.
Why Kodiak Sciences Skyrocketed Today
The biotech is developing innovative therapies for people with eye diseases.
KOD Stock Cracks September’s Top 5 Biotech Gainers On Eye Drug Win — But ‘Pharma Bro’ Shkreli Says It ‘Still Sucks’
Martin Shkreli, who said he was short KOD before the readout, questioned Zenkuda’s edge over Eylea and dismissed the added IL-6 targeting in KSI-501.
Kodiak Sciences (KOD) Climbs Nearly 3x on Promising Wet AMD Trial
Kodiak Sciences Inc. (NASDAQ:KOD) saw its share price nearly triple on Monday to a near five-year high, as investors loaded positions to cheer strong clinical trial results for its wet AMD treatment candidate. In intraday trading, the stock soared by as much as 196 percent before trimming gains to finish the session just up by […]
MongoDB, Kodiak Sciences, Navitas Semiconductor, Boeing and Nvidia: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed lower on Monday, with the Dow Jones Industrial Average falling 0.67% to 51,481.51.
Nvidia, Micron, Meta, Kodiak Sciences, MongoDB, SpaceX, and More Stocks That Explain Today’s Market
FEATURE Stocks fell Monday as waning peace talks between the U.S. and Iran drove oil prices and bond yields higher. Nvidia rose 2.2%. The chip maker said it would launch the largest-ever U.S. stock buyback of $150 billion, bringing the total buyback authorization to $235 billion.
Why This Regeneron Eye Rival Just Catapulted More Than 120%
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.
Sector Update: Healthcare Stocks Rise Late Afternoon
Healthcare stocks rose late Monday afternoon with the NYSE Healthcare Index and the State Street Hea
Inside the Eye-Drug Breakthrough That Sent Kodiak Sciences Up 172%
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Kodiak Sciences soars as Zenkuda, tabirafusp-ted hit primary endpoints in phase III wet AMD trial
Kodiak Sciences Inc (NASDAQ:KOD) surged after Zenkuda and tabirafusp-ted met their primary endpoints in the phase III DAYBREAK trial for wet age-related macular degeneration. Shares gained over 162% by midday Monday following the announcement. Both experimental drugs demonstrated...
Kodiak skyrockets on positive study data for 2 eye drugs
The Phase 3 findings suggested Kodiak might have multiple threats to Regeneron’s Eylea and added more than $3 billion to the company’s market value.
Kodiak’s stock rallies on Phase III wAMD success
If approved, Zenkuda will compete with blockbuster wAMD sellers like Eylea and Vabysmo.
Kodiak Sciences Soars 141% on “Truly Impressive” Pivotal Wet AMD Trial Win
Key TakeawaysKodiak Sciences shares jumped about 141% after its drug Zenkuda met its primary endpoint in the pivotal Phase 3 DAYBREAK trial in wet AMD. Zenkuda’s edge is durability: it matched aflibercept on vision gains while 54% of its patients were on 6-month dosing under strict retreatment rules.
Gold Tumbles Over 3%; MongoDB Shares Move Lower
U.S. stocks fell Monday, led by a 150-point Nasdaq drop. Energy rose, communication services slid; Knorex and Kodiak surged, while MongoDB tumbled.
Kodiak Stock Soars (Again) As Data Shows Long-Lasting Eye Meds Are 'Real Deal'
Kodiak Sciences Inc. stock jumps 140% on Phase 3 DAYBREAK wet AMD results. Click for this updated look at KOD and see if it belongs in your portfolio.
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
This Biotech Company Added Nearly $3B To Its Market Cap – Here’s Why KOD Stock Is Ripping Today
Kodiak Sciences shares saw their biggest ever single-day gains after the company posted positive Phase 3 data for 2 therapies targeting wet age-related macular degeneration.
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results Transcript
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results September 28, 2026 8:30 AM EDTCompany ParticipantsVictor Perlroth -...
UBS Maintains Buy on Kodiak Sciences, Raises Price Target to $120
UBS analyst Michael Yee maintains Kodiak Sciences (NASDAQ:KOD) with a Buy and raises the price target from $80 to $120.
Kodiak Sciences stock soars on positive AMD trial data
Investing.com -- Kodiak Sciences Inc (NASDAQ:KOD) shares surged as much as 90% in premarket trading Monday following positive results from its Phase 3 DAYBREAK study in wet age-related macular degeneration.
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares moved upwards by 172.3% to $88.08 during Monday's regular session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) shares moved
Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus
Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.
Dow Dips Over 200 Points; Dallas Fed’s Manufacturing Index Declines In September
U.S. stocks fell Monday as the Dow dropped 200+ points; Nasdaq and S&P 500 also slid. Health care rose, while communication services lagged.
Kodiak Sciences Inc. (KOD) Discusses DAYBREAK Topline Data and Primary Endpoint Results - Slideshow
2026-09-28. The following slide deck was published by Kodiak Sciences Inc.
These stocks are moving in today's pre-market session
Before the US market kicks off on Monday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.
HC Wainwright & Co. Maintains Buy on Kodiak Sciences, Raises Price Target to $96
HC Wainwright & Co. analyst Matthew Caufield maintains Kodiak Sciences (NASDAQ:KOD) with a Buy and raises the price target from $58 to $96.
Kodiak Sciences Stock Pops 70% After Eye-Disease Drugs Pass Key Trial
Kodiak Sciences plans to file for regulatory approval of one drug candidate, Zenkuda, following its success in a trial for wet age-related macular degeneration.
Regeneron Eylea Feels the Pinch as Kodiak Advances Extended Dosing for Eye Drug
Regeneron stock drops as Kodiak Sciences reports Phase 3 wAMD data showing Zenkuda rivals Eylea with extended six-month dosing schedules.
Kodiak Sciences Shares Rise After DAYBREAK Phase 3 Trial Results
Kodiak Sciences (NASDAQ:KOD) shares rose 31. 9% in pre-market trading after the company released topline results from its DAYBREAK pivotal Phase 3 study evaluating two investigational therapies in patients with wet age-related macular degeneration.
Zenkuda and tabirafusp-ted Meet Primary Endpoints in Pivotal DAYBREAK Trial in wAMD, with Zenkuda Demonstrating a Potential New Standard-of-Care Profile with Strong Immediacy and Sustained Clinical Effect with Majority of Patients on 24-week Dosing Interval Using Strict Treat-to-Dryness Real World Retreatment Criteria.
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the primary endpoints were met for both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501) in the Phase 3 DAYBREAK study in patients with wet age-related macular degeneration (wAMD). The DAYBREAK study in wAMD demonstrated that both Zenkuda and tabirafusp-ted achieved non-inferiority in vision g
Kodiak Sciences Says Eye Drug on Par with Regeneron's Medicine
Kodiak Sciences announced positive data from its Phase 3 DAYBREAK study for its eye treatments Zenkuda and tabirafusp-ted.
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Kodiak Sciences (NASDAQ:KOD) shares increased by 57.4% to $50.93 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Accuray (NASDAQ:ARAY) stock moved
Kodiak Sciences Says Phase 3 DAYBREAK Study Met Primary Endpoints With Zenkuda (Tarcocimab Tedromer) And Tabirafusp-ted (KSI-501) Showing Non-inferiority In Vision Gains For Wet Age-related Macular Degeneration Vs. Aflibercept At Year One
Zenkuda (tarcocimab tedromer) met the primary endpoint (p-value of 0.0007) demonstrating meaningful vision gains as well as rapid and sustained retinal drying with the majority of patients (54%) on 6-month dosing,
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration
Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that the company will report topline results from DAYBREAK, a Phase 3 study evaluating both Zenkuda TM (tarcocimab tedromer) and KSI-501 (tabirafusp alfa tedromer) for the treatment of patients with wet age-related macular degeneration, on Monday, September 28, 2026.
Kodiak Sciences To Host Webcast To Report Phase 3 DAYBREAK Topline Results For Wet AMD Candidates On September 28 At 8:30 AM Eastern Time
Kodiak Sciences to Host Webcast on Monday, September 28 PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (NASDAQ:KOD), a precommercial retina-focused biotechnology company committed to researching,
Upcoming DAYBREAK Trial Results in Wet AMD Could Be A Game Changer For Kodiak Sciences (KOD)
Kodiak Sciences recently highlighted that it is on track to report top-line Phase III DAYBREAK results for Zenkuda (tarcocimab tedromer) and KSI-501 in treatment-naïve wet age-related macular degeneration, part of a broader push into retinal vascular diseases that it views as a roughly US$15.00 billion anti-VEGF market. The company’s additional late-stage programs, including the PEAK and PINNACLE trials in macular edema and the ALTO study of KSI-501 in diabetic macular edema, position its...
Goldman Sachs Reinstates Neutral on Kodiak Sciences, Announces $36 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Kodiak Sciences (NASDAQ:KOD) with a Neutral and announces $36 price target.
Kodiak Sciences (KOD) Stock Looks Overvalued After Its 15x Run
Kodiak Sciences has seen its share price move sharply in recent years, which puts a spotlight on whether the current US$31.52 level is supported by the company’s book value. With that kind of price action, the key issue for you is how much of Kodiak Sciences’ balance sheet strength is already reflected in today’s valuation. Over the past 3 years the stock has delivered a very large gain of about 15x. As a result, any discussion of value now needs to start with how much balance sheet support...
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines.
4 Biotech Stocks With Key Clinical Readouts Expected This Fall
KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.
Costco, BlackBerry To Headline Earnings In A Muted Week
Preview next weekâs market movers: Fed, yields, PMI, jobless claims, durable goods, earnings (Costco, BB), dividends & IPOs. Read here for more.
HC Wainwright & Co. Reiterates Buy on Kodiak Sciences, Maintains $58 Price Target
HC Wainwright & Co. analyst Matthew Caufield reiterates Kodiak Sciences (NASDAQ:KOD) with a Buy and maintains $58 price target.
Kodiak Sciences: Daybreak Needs To Deliver More Than A Passing Grade
Kodiak expects Phase 3 DAYBREAK results for Zenkuda and KSI-501 this month in wet AMD. Read why KOD stock is a hold.
3 Small-Cap Biotechs With Binary Catalysts on the Calendar
Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.
Kodiak Sciences (KOD) Races Toward Three Make-Or-Break Trial Verdicts
On August 13, Kodiak Sciences Inc. (NASDAQ:KOD) reported second-quarter financial results for the period ended June 30, alongside an update on its three late-stage eye disease programs. The clinical-stage biotech told investors it now sits within months of three separate Phase 3 readouts, a stretch CEO Victor Perlroth called the payoff of years of disciplined […]
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-25 | PERLROTH VICTOR | -314,684 | - | - |
| 2026-09-25 | PERLROTH VICTOR | -365,840 | - | - |
| 2026-09-25 | PERLROTH VICTOR | -600,000 | - | - |
| 2026-09-25 | PERLROTH VICTOR | +314,684 | $3.95 | $1,243,002 |
| 2026-09-25 | PERLROTH VICTOR | +365,840 | $2.49 | $910,942 |
| 2026-09-25 | PERLROTH VICTOR | +600,000 | $5.38 | $3,228,000 |
| 2026-07-15 | PERLROTH VICTOR | +100,000 | - | - |
| 2026-07-15 | BORGESON JOHN A. | +66,500 | - | - |
| 2026-06-30 | Dahiyat Bassil I | +17,731 | - | - |
| 2026-06-30 | Bancroft Charles A | +17,731 | - | - |
| 2026-06-30 | Levy Richard S | +17,731 | - | - |
| 2026-06-30 | Yang Taiyin | +17,731 | - | - |
| 2026-06-30 | PROFUSEK ROBERT | +17,731 | - | - |
| 2026-06-30 | BAKER BROS. ADVISORS LP | +17,731 | - | - |
| 2026-06-30 | BAKER BROS. ADVISORS LP | +17,731 | - | - |
| 2026-06-04 | BORGESON JOHN A. | -30,000 | - | - |
| 2026-06-04 | BORGESON JOHN A. | -4,104 | $34.67 | $142,286 |
| 2026-06-04 | BORGESON JOHN A. | -25,896 | $34.01 | $880,723 |
| 2026-06-04 | BORGESON JOHN A. | +30,000 | $1.04 | $31,200 |
| 2026-04-15 | BORGESON JOHN A. | -28,614 | - | - |
| 2026-04-15 | BORGESON JOHN A. | +28,614 | $1.04 | $29,759 |
| 2026-04-02 | BORGESON JOHN A. | -30,000 | - | - |
| 2026-04-02 | BORGESON JOHN A. | -600 | $41.77 | $25,062 |
| 2026-04-02 | BORGESON JOHN A. | -4,231 | $40.88 | $172,963 |
| 2026-04-02 | BORGESON JOHN A. | -12,477 | $40.29 | $502,698 |
| 2026-04-02 | BORGESON JOHN A. | -12,692 | $39.14 | $496,765 |
| 2026-04-02 | BORGESON JOHN A. | +30,000 | $1.04 | $31,200 |
| 2026-03-25 | PERLROTH VICTOR | -300,000 | - | - |
| 2026-03-25 | PERLROTH VICTOR | +300,000 | $1.04 | $312,000 |
| 2026-03-18 | PERLROTH VICTOR | +175,000 | - | - |
| 2025-12-26 | PERLROTH VICTOR | -12,500 | - | - |
| 2025-12-18 | BAKER JULIAN | +2,391,268 | $23 | $54,999,164 |
| 2025-12-18 | BAKER JULIAN | +217,428 | $23 | $5,000,844 |